Clinical Trial Update: Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis [Phase 2]

View source ↗

Summary

Open-label Phase 2 study assessing safety, pharmacokinetics, and exploratory efficacy of OPRX-106 in adults with active mild to moderate ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• OPRX-106 (TNFR-Fc fusion protein)

Snippet

Sponsor: Protalix | Conditions: Ulcerative Colitis | Phase 2 | Status: UNKNOWN